Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
J Chem Inf Model ; 64(3): 621-626, 2024 Feb 12.
Artículo en Inglés | MEDLINE | ID: mdl-38276895

RESUMEN

Using a combination of multisite λ-dynamics (MSλD) together with in vitro IC50 assays, we evaluated the polypharmacological potential of a scaffold currently in clinical trials for inhibition of human neutrophil elastase (HNE), targeting cardiopulmonary disease, for efficacious inhibition of Proteinase 3 (PR3), a related neutrophil serine proteinase. The affinities we observe suggest that the dihydropyrimidinone scaffold can serve as a suitable starting point for the establishment of polypharmacologically targeting both enzymes and enhancing the potential for treatments addressing diseases like chronic obstructive pulmonary disease.


Asunto(s)
Polifarmacología , Humanos , Mieloblastina , Proteínas Inhibidoras de Proteinasas Secretoras
2.
Molecules ; 24(6)2019 Mar 19.
Artículo en Inglés | MEDLINE | ID: mdl-30893775

RESUMEN

Development of inhibitors for ubiquitin pathway has been suggested as a promising strategy to treat several types of cancers, which has been showcased by recent success of a series of novel anticancer drugs based on inhibition of ubiquitin pathways. Although the druggability of enzymes in ubiquitin pathways has been demonstrated, ubiquitin itself, the main agent of the pathway, has not been targeted. Whereas conventional enzyme inhibitors are used to silence the ubiquitination or reverse it, they cannot disrupt the binding activity of ubiquitin. Herein, we report that the scaffolds of sulfonated aryl diazo compounds, particularly Congo red, could disrupt the binding activity of ubiquitin, resulting in the activity equivalent to inhibition of ubiquitination. NMR mapping assay demonstrated that the chemical directly binds to the recognition site for ubiquitin processing enzymes on the surface of ubiquitin, and thereby blocks the binding of ubiquitin to its cognate receptors. As a proof of concept for the druggability of the ubiquitin molecule, we demonstrated that Congo red acted as an intracellular inhibitor of ubiquitin recognition and binding, which led to inhibition of ubiquitination, and thereby, could be used as a sensitizer for conventional anticancer drugs, doxorubicin.


Asunto(s)
Ubiquitina/metabolismo , Supervivencia Celular/efectos de los fármacos , Rojo Congo , Enzimas Desubicuitinizantes/metabolismo , Doxorrubicina/farmacología , Células HCT116 , Humanos , Espectroscopía de Resonancia Magnética , Unión Proteica , Transducción de Señal/efectos de los fármacos , Ubiquitinación/efectos de los fármacos
3.
Chemistry ; 22(5): 1614-7, 2016 Jan 26.
Artículo en Inglés | MEDLINE | ID: mdl-26660291

RESUMEN

An efficient thioamination of alkenes mediated by iodine(III) reagents is described. The use of different sulfur nucleophiles allows the flexible synthesis of 1,2-aminothiols from alkenes. By employing chiral iodine(III) reagents, a stereoselective version of the thioamination protocol has also been developed.

4.
J Biol Chem ; 289(11): 7702-17, 2014 Mar 14.
Artículo en Inglés | MEDLINE | ID: mdl-24469461

RESUMEN

Hydroxynaphthoquinone-based inhibitors of the lysine acetyltransferase KAT3B (p300), such as plumbagin, are relatively toxic. Here, we report that free thiol reactivity and redox cycling properties greatly contribute to the toxicity of plumbagin. A reactive 3rd position in the naphthoquinone derivatives is essential for thiol reactivity and enhances redox cycling. Using this clue, we synthesized PTK1, harboring a methyl substitution at the 3rd position of plumbagin. This molecule loses its thiol reactivity completely and its redox cycling ability to a lesser extent. Mechanistically, non-competitive, reversible binding of the inhibitor to the lysine acetyltransferase (KAT) domain of p300 is largely responsible for the acetyltransferase inhibition. Remarkably, the modified inhibitor PTK1 was a nearly non-toxic inhibitor of p300. The present report elucidates the mechanism of acetyltransferase activity inhibition by 1,4-naphthoquinones, which involves redox cycling and nucleophilic adduct formation, and it suggests possible routes of synthesis of the non-toxic inhibitor.


Asunto(s)
Proteína p300 Asociada a E1A/antagonistas & inhibidores , Inhibidores Enzimáticos/química , Naftoquinonas/química , Sitios de Unión , Línea Celular Tumoral , Supervivencia Celular , Proteína p300 Asociada a E1A/química , Células HEK293 , Células HeLa , Humanos , Cinética , Lisina/química , Oxidación-Reducción , Estructura Terciaria de Proteína , Especies Reactivas de Oxígeno , Relación Estructura-Actividad , Compuestos de Sulfhidrilo/química
5.
J Neurosci ; 33(26): 10698-712, 2013 Jun 26.
Artículo en Inglés | MEDLINE | ID: mdl-23804093

RESUMEN

Although the brain functions of specific acetyltransferases such as the CREB-binding protein (CBP) and p300 have been well documented using mutant transgenic mice models, studies based on their direct pharmacological activation are still missing due to the lack of cell-permeable activators. Here we present a small-molecule (TTK21) activator of the histone acetyltransferases CBP/p300, which, when conjugated to glucose-based carbon nanosphere (CSP), passed the blood-brain barrier, induced no toxicity, and reached different parts of the brain. After intraperitoneal administration in mice, CSP-TTK21 significantly acetylated histones in the hippocampus and frontal cortex. Remarkably, CSP-TTK21 treatment promoted the formation of long and highly branched doublecortin-positive neurons in the subgranular zone of the dentate gyrus and reduced BrdU incorporation, suggesting that CBP/p300 activation favors maturation and differentiation of adult neuronal progenitors. In addition, mRNA levels of the neuroD1 differentiation marker and BDNF, a neurotrophin required for the terminal differentiation of newly generated neurons, were both increased in the hippocampus concomitantly with an enrichment of acetylated-histone on their proximal promoter. Finally, we found that CBP/p300 activation during a spatial training, while not improving retention of a recent memory, resulted in a significant extension of memory duration. This report is the first evidence for CBP/p300-mediated histone acetylation in the brain by an activator molecule, which has beneficial implications for the brain functions of adult neurogenesis and long-term memory. We propose that direct stimulation of acetyltransferase function could be useful in terms of therapeutic options for brain diseases.


Asunto(s)
Proteína de Unión a CREB/metabolismo , Activadores de Enzimas/farmacología , Memoria/efectos de los fármacos , Neurogénesis/efectos de los fármacos , Factores de Transcripción p300-CBP/metabolismo , Acetiltransferasas/metabolismo , Animales , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/metabolismo , Encéfalo/crecimiento & desarrollo , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Recuento de Células , Núcleo Celular/metabolismo , Inmunoprecipitación de Cromatina , Dendritas/metabolismo , Dendritas/ultraestructura , Técnica del Anticuerpo Fluorescente , Hipocampo/citología , Hipocampo/metabolismo , Histona Acetiltransferasas/metabolismo , Histonas/aislamiento & purificación , Inmunohistoquímica , Masculino , Ratones , Ratones Endogámicos C57BL , Nanosferas , Neuronas/metabolismo , Neuronas/ultraestructura , Reacción en Cadena en Tiempo Real de la Polimerasa
6.
Chemistry ; 20(41): 13113-6, 2014 Oct 06.
Artículo en Inglés | MEDLINE | ID: mdl-25156303

RESUMEN

A new chiral thiohydantoin catalyst is used for the stereoselective iodoamination of alkenes. N-iodosuccinimide as the source of the electrophilic iodine is activated by catalytic amounts of different additives which also influence the regioselectivity of some cyclizations.

7.
Chemistry ; 20(32): 9910-3, 2014 Aug 04.
Artículo en Inglés | MEDLINE | ID: mdl-25042733

RESUMEN

Vicinal diamines constitute one the most important functional motif in organic chemistry because of its wide occurrence in a variety of biological and pharmaceutical molecules. We report an efficient metal-free, highly stereoselective intramolecular diamination using a novel chiral hypervalent iodine reagent together with its application as an efficient catalyst for the synthesis of diamines.

8.
Angew Chem Int Ed Engl ; 53(23): 5993-7, 2014 Jun 02.
Artículo en Inglés | MEDLINE | ID: mdl-24846685

RESUMEN

The functionalization of carbonyl compounds in the α-position has gathered much attention as a synthetic route because of the wide biological importance of such products. Through polarity reversal, or "umpolung", we show here that typical nucleophiles, such as oxygen, nitrogen, and even carbon nucleophiles, can be used for addition reactions after tethering them to enol ethers. Our findings allow novel retrosynthetic planning and rapid assembly of structures previously accessible only by multistep sequences.

9.
Indian J Med Res ; 137(6): 1128-44, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23852294

RESUMEN

BACKGROUND & OBJECTIVES: The complementary and alternative medicines (CAM) have not been systematically evaluated for the management of HIV/AIDS patients. In a prospective, single-site, open-label, non-randomized, controlled, pilot trial, we evaluated a polyherbal formulation (PHF) for its safety and efficacy in treating subjects with HIV-AIDS. METHODS: A total of 32 and 31 subjects were enrolled under the PHF and highly active antiretroviral treatment (HAART) arms, respectively, and followed up for a period of 24 months. Plasma viral RNA, CD4 cell count and blood chemistry were monitored at 3-month intervals. Following mid-term safety evaluation, 12 subjects from the PHF arm were shifted to HAART and were followed separately as PHF-to-HAART arm, for the rest of the period. RESULTS: The HAART arm was characterized by significant improvements in CD4 cell count (154.4 cells/µl/year, P<0.001) and reduction in plasma viral load within 3 to 6 months (-0.431+ 0.004 log 10 IU/month, P<0.001). In contrast, the PHF arm showed a profile of CD4 cell loss at remarkably slower kinetics (14.3 cells/µl/year, P=0.021) and insignificant reduction in the viral load. The PHF and HAART arms did not differ significantly in the occurrence of AIDS-related illnesses over the study period of 24 months. In the PHF-to-HAART arm, the rates of CD4 count and reduction in viral load were significant and comparable to that of the HAART group. In the PHF arm, at 1 month, a significant increase in CD4 cell count and a concomitant decrease in viral load were seen. INTERPRETATION & CONCLUSIONS: The PHF appears to have provided protection by delaying the kinetics of CD4 cell reduction. Given the several study limitations, drawing assertive inferences from the data is challenging. Future studies with a stringent study design are warranted to confirm these findings.


Asunto(s)
Infecciones por VIH/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Adulto , Fármacos Anti-VIH/uso terapéutico , Terapia Antirretroviral Altamente Activa , Recuento de Linfocito CD4 , Linfocitos T CD4-Positivos/efectos de los fármacos , Terapias Complementarias , Femenino , Humanos , India , Masculino , Persona de Mediana Edad , Seguridad del Paciente , Proyectos Piloto , Estudios Prospectivos , ARN Viral/sangre , Resultado del Tratamiento , Carga Viral/efectos de los fármacos
10.
ACS Omega ; 4(3): 6035-6043, 2019 Mar 31.
Artículo en Inglés | MEDLINE | ID: mdl-31459751

RESUMEN

A novel approach has been developed for the synthesis of a wide range of α-ketoacetals by the reaction of alkyl/aryl methyl ketones and aliphatic alcohols in the presence of selenium dioxide catalyzed by p-toluenesufonic acid. This method represents a general route to obtain a wide variety of α-ketoacetals in a simple, rapid, and practical manner. This approach is particularly attractive because of the easy availability of the starting materials, mild reaction temperature, and good yields of the products. The resulting α-ketoacetals are of much synthetic value as organic intermediates.

11.
mBio ; 10(4)2019 07 09.
Artículo en Inglés | MEDLINE | ID: mdl-31289190

RESUMEN

Mannitol-1-phosphate dehydrogenase (M1PDH) is a key enzyme in Staphylococcus aureus mannitol metabolism, but its roles in pathophysiological settings have not been established. We performed comprehensive structure-function analysis of M1PDH from S. aureus USA300, a strain of community-associated methicillin-resistant S. aureus, to evaluate its roles in cell viability and virulence under pathophysiological conditions. On the basis of our results, we propose M1PDH as a potential antibacterial target. In vitro cell viability assessment of ΔmtlD knockout and complemented strains confirmed that M1PDH is essential to endure pH, high-salt, and oxidative stress and thus that M1PDH is required for preventing osmotic burst by regulating pressure potential imposed by mannitol. The mouse infection model also verified that M1PDH is essential for bacterial survival during infection. To further support the use of M1PDH as an antibacterial target, we identified dihydrocelastrol (DHCL) as a competitive inhibitor of S. aureus M1PDH (SaM1PDH) and confirmed that DHCL effectively reduces bacterial cell viability during host infection. To explain physiological functions of SaM1PDH at the atomic level, the crystal structure of SaM1PDH was determined at 1.7-Å resolution. Structure-based mutation analyses and DHCL molecular docking to the SaM1PDH active site followed by functional assay identified key residues in the active site and provided the action mechanism of DHCL. Collectively, we propose SaM1PDH as a target for antibiotic development based on its physiological roles with the goals of expanding the repertory of antibiotic targets to fight antimicrobial resistance and providing essential knowledge for developing potent inhibitors of SaM1PDH based on structure-function studies.IMPORTANCE Due to the shortage of effective antibiotics against drug-resistant Staphylococcus aureus, new targets are urgently required to develop next-generation antibiotics. We investigated mannitol-1-phosphate dehydrogenase of S. aureus USA300 (SaM1PDH), a key enzyme regulating intracellular mannitol levels, and explored the possibility of using SaM1PDH as a target for developing antibiotic. Since mannitol is necessary for maintaining the cellular redox and osmotic potential, the homeostatic imbalance caused by treatment with a SaM1PDH inhibitor or knockout of the gene encoding SaM1PDH results in bacterial cell death through oxidative and/or mannitol-dependent cytolysis. We elucidated the molecular mechanism of SaM1PDH and the structural basis of substrate and inhibitor recognition by enzymatic and structural analyses of SaM1PDH. Our results strongly support the concept that targeting of SaM1PDH represents an alternative strategy for developing a new class of antibiotics that cause bacterial cell death not by blocking key cellular machinery but by inducing cytolysis and reducing stress tolerance through inhibition of the mannitol pathway.


Asunto(s)
Antibacterianos/farmacología , Manitol/metabolismo , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Deshidrogenasas del Alcohol de Azúcar/química , Deshidrogenasas del Alcohol de Azúcar/metabolismo , Animales , Femenino , Macrófagos/microbiología , Masculino , Staphylococcus aureus Resistente a Meticilina/enzimología , Staphylococcus aureus Resistente a Meticilina/genética , Ratones , Ratones Endogámicos C57BL , Simulación del Acoplamiento Molecular , Mutación , Células RAW 264.7 , Infecciones Estafilocócicas/microbiología , Deshidrogenasas del Alcohol de Azúcar/genética , Virulencia
12.
J Med Chem ; 61(23): 10473-10487, 2018 12 13.
Artículo en Inglés | MEDLINE | ID: mdl-30388007

RESUMEN

As an alternative strategy to fight antibiotic resistance, two-component systems (TCSs) have emerged as novel targets. Among TCSs, master virulence regulators that control the expression of multiple virulence factors are considered as excellent antivirulence targets. In Staphylococcus aureus, virulence factor expression is tightly regulated by a few master regulators, including the SaeRS TCS. In this study, we used a SaeRS GFP-reporter system to screen natural compound inhibitors of SaeRS, and identified xanthoangelol B 1, a prenylated chalcone from Angelica keiskei as a hit. We have synthesized 1 and its derivative PM-56 and shown that 1 and PM-56 both had excellent inhibitory potency against the SaeRS TCS, as demonstrated by various in vitro and in vivo experiments. As a mode of action, 1 and PM-56 were shown to bind directly to SaeS and inhibit its histidine kinase activity, which suggests a possibility of a broad spectrum inhibitor of histidine kinases.


Asunto(s)
Chalcona/análogos & derivados , Diseño de Fármacos , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/metabolismo , Factores de Virulencia/biosíntesis , Antibacterianos/síntesis química , Antibacterianos/química , Antibacterianos/farmacología , Chalcona/síntesis química , Chalcona/química , Chalcona/farmacología , Técnicas de Química Sintética
13.
Chem Biol Drug Des ; 87(6): 958-67, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-26808391

RESUMEN

Aurora kinases are the most commonly targeted mitotic kinases in the intervention of cancer progression. Here, we report a resorcinol derivative, 5-methyl-4-(2-thiazolylazo) resorcinol (PTK66), a dual inhibitor of Aurora A and Aurora B kinases. PTK66 is a surface binding non-ATP analogue inhibitor that shows a mixed pattern of inhibition against both of Aurora A and B kinases. The in vitro IC50 is approximately 47 and 40 µm for Aurora A and Aurora B kinases, respectively. In cellular systems, PTK66 exhibits a substantially low cytotoxicity at micromolar concentrations but it can induce aneuploidy under similar dosages as a consequence of Aurora kinase inhibition. This result was corroborated by a drop in the histone H3 (S10) phosphorylation level detected via Western blot analysis using three different cell types. Altogether, our findings indicate that the ligand containing resorcinol backbone is one of the novel scaffolds targeting the Aurora family of kinases, which could be a target for antineoplastic drug development.


Asunto(s)
Adenosina Trifosfato , Aurora Quinasa A , Aurora Quinasa B , Inhibidores de Proteínas Quinasas , Resorcinoles , Adenosina Trifosfato/análogos & derivados , Adenosina Trifosfato/química , Adenosina Trifosfato/farmacología , Aurora Quinasa A/antagonistas & inhibidores , Aurora Quinasa A/química , Aurora Quinasa A/metabolismo , Aurora Quinasa B/antagonistas & inhibidores , Aurora Quinasa B/química , Aurora Quinasa B/metabolismo , Línea Celular , Humanos , Inhibidores de Proteínas Quinasas/química , Inhibidores de Proteínas Quinasas/farmacología , Resorcinoles/química , Resorcinoles/farmacología
14.
ACS Chem Biol ; 8(6): 1311-23, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23570531

RESUMEN

PCAF (KAT2B) belongs to the GNAT family of lysine acetyltransferases (KAT) and specifically acetylates the histone H3K9 residue and several nonhistone proteins. PCAF is also a transcriptional coactivator. Due to the lack of a PCAF KAT-specific small molecule inhibitor, the exclusive role of the acetyltransferase activity of PCAF is not well understood. Here, we report that a natural compound of the hydroxybenzoquinone class, embelin, specifically inhibits H3Lys9 acetylation in mice and inhibits recombinant PCAF-mediated acetylation with near complete specificity in vitro. Furthermore, using embelin, we have identified the gene networks that are regulated by PCAF during muscle differentiation, further highlighting the broader regulatory functions of PCAF in muscle differentiation in addition to the regulation via MyoD acetylation.


Asunto(s)
Acetilación/efectos de los fármacos , Benzoquinonas/farmacología , Factores de Transcripción p300-CBP/antagonistas & inhibidores , Factores de Transcripción p300-CBP/metabolismo , Animales , Benzoquinonas/química , Diferenciación Celular , Línea Celular , Regulación de la Expresión Génica/efectos de los fármacos , Células HEK293 , Histonas/metabolismo , Humanos , Ratones , Proteína MioD/metabolismo , Mioblastos/citología , Mioblastos/metabolismo , Proteínas Recombinantes/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA